查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085844

介入性腫瘤學市場：按產品類型、手術類型、癌症類型和最終用戶分類的全球市場預測 – 2026-2032 年

Interventional Oncology Market by Product Type, Procedure Type, Cancer Type, End-Use - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，介入性腫瘤學市場將成長至 45.8 億美元，複合年成長率為 7.65%。

主要市場統計數據
基準年 2025 27.3億美元
預計年份：2026年 29.3億美元
預測年份 2032 45.8億美元
複合年成長率 (%) 7.65%

介入性腫瘤執行摘要

介入性腫瘤學現已成為多學科癌症治療的核心領域，它利用影像引導的癌症治療技術，對固態腫瘤進行微創、精準的診斷、消融、栓塞和姑息治療。此領域在肝癌、伴隨肝轉移的結直腸癌、肺部病變、腎臟腫瘤、骨轉移以及某些胰臟和軟組織腫瘤的治療中最為成熟。在這些疾病中，腫瘤消融、經動脈化療栓塞術（TACE）、經動脈放射性栓塞術（TARE/Y-90）和標靶切片檢查可以作為手術、全身性治療和放射線治療的補充手段。

介入性腫瘤學領域的變革性變化

介入性腫瘤學領域正從以手術為主的服務模式轉向整合式、針對特異性疾病的癌症治療計畫。醫院正在加速將介入放射科醫師納入腫瘤委員會、肝癌門診、肺結節計畫以及轉移性疾病的治療路徑中，使患者能夠在早期階段接受消融、栓塞和局部/區域治療的評估，而不是等到多種治療失敗後才進行評估。

人工智慧在介入性腫瘤學中的累積影響

人工智慧 (AI) 正在對整個介入性腫瘤學工作流程產生累積影響。在篩檢和診斷階段，AI 驅動的影像工具能夠幫助檢測病灶、界定腫瘤邊界，並確定需要專家會診的病例的優先順序。在治療計劃階段，分割和放射組學技術有助於進行體積評估、消融邊緣估計以及選擇適合影像引導癌症治療的患者。

關鍵區域洞察：全球介入腫瘤學需求

由於亞太地區肝癌、肺癌、胃癌和大腸癌的高發生率，預計該地區的介入性腫瘤學將快速發展。中國、日本、韓國、印度和澳洲等主要市場持續投資於先進的影像技術和癌症治療基礎設施。北美仍然是全球創新中心，這得益於大規模學術癌症中心、完善的影像引導手術醫療保險報銷機制，以及對腫瘤消融、經導管動脈化療栓塞術（TACE）和釔-90放射性栓塞術的積極應用。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協市場，由於癌症發生率上升以及各國政府擴大三級醫療服務能力，介入腫瘤學的重要性日益凸顯。新加坡、泰國、馬來西亞、印尼、越南和菲律賓在引入介入性腫瘤學方面正處於不同的發展階段。在海灣合作理事會（GCC）國家，隨著國家癌症戰略的訂定、先進醫院的建設、癌症中心的開發以及醫療旅遊的發展，對介入腫瘤學的需求正在加速成長，尤其是在沙烏地阿拉伯、阿拉伯聯合大公國和卡達。

重點國家洞察：介入腫瘤學的首選市場

美國在學術介入腫瘤學、臨床試驗、釔-90放射性栓塞術、腫瘤消融術和多學科癌症診療方面處於主導。同時，在加拿大，儘管都市區癌症中心正在逐步推廣這些技術，但偏遠和農村地區仍然面臨地理上的准入挑戰。在墨西哥和巴西，微創腫瘤服務正在透過主要的公立和私立醫院不斷擴展，但成本效益、保險報銷差異和地區差異仍然是限制因素。在歐洲，英國、德國、法國、義大利和西班牙已經建立了介入放射學網路和基於指南的腫瘤診療體系，而在俄羅斯，腫瘤治療的需求量很大，但各地區的醫療資源分配不均。

為介入性腫瘤學領域的領導者提供的實用建議

產業領導者應基於疾病特異性治療路徑而非單一手術流程來建構介入性腫瘤學計畫。短期內，最具前景的領域包括肝細胞癌、結直腸癌肝轉移、肺癌、腎癌和骨轉移的姑息治療，在這些領域，影像引導治療可以縮短康復時間，並透過多學科協作最佳化治療方案。

調查方法

本執行摘要是基於對公共衛生數據、癌症流行病學、臨床實踐指南、同行評審文獻、監管資訊以及介入腫瘤學領域已證實的實施模式的系統性回顧。主要參考文獻包括國際公認的權威資訊來源，例如國際癌症研究機構 (IARC)、世界衛生組織 (WHO)、各國癌症機構以及腫瘤學和介入放射學專業學會的指南。

結論：介入腫瘤學作為策略性成長平台

介入性腫瘤學正從一項專門的手術領域轉向一項策略性的癌症治療能力。癌症發生率的上升、先進的影像技術、微創治療、人工智慧驅動的治療計劃以及多學科決策，都在推動其在診斷、局部腫瘤控制、安寧療護和聯合治療等各個環節中發揮越來越重要的作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 介入性腫瘤市場：依產品類型分類

  • 消融裝置
  • 栓塞裝置
  • 支援和存取設備

第8章 介入性腫瘤學市場：依手術類型分類

  • 腫瘤消融術
  • 血管介入
  • 腫瘤切片檢查程序
  • 安寧療護

第9章 介入性腫瘤學市場：依癌症類型分類

  • 肝癌
  • 肺癌
  • 腎癌
  • 乳癌

第10章 介入性腫瘤學市場：依最終用途分類

  • 醫院
  • 專科診所

第11章 介入性腫瘤學市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 介入性腫瘤市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 介入性腫瘤學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Accuray Incorporated
  • Baxter International Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cook Medical Inc.
  • GE HealthCare Technologies Inc.
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips NV
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Profound Medical Corp.
  • Siemens Healthineers AG
  • Sirtex Medical Limited
  • Teleflex Incorporated
  • Terumo Corporation
  • Varian Medical Systems, Inc.
Product Code: MRR-43127F7279CE

The Interventional Oncology Market is projected to grow by USD 4.58 billion at a CAGR of 7.65% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.73 billion
Estimated Year [2026] USD 2.93 billion
Forecast Year [2032] USD 4.58 billion
CAGR (%) 7.65%

Interventional Oncology Executive Summary

Interventional oncology is now a core pillar of multidisciplinary cancer care, using image-guided cancer therapy to diagnose, ablate, embolize, and palliate solid tumors with minimally invasive precision. The field is most established in liver cancer, metastatic colorectal cancer to the liver, lung lesions, renal tumors, bone metastases, and selected pancreatic and soft-tissue indications, where tumor ablation, transarterial chemoembolization (TACE), transarterial radioembolization (TARE/Y-90), and targeted biopsy can complement surgery, systemic therapy, and radiation.

Demand is structurally supported by the global cancer burden. The International Agency for Research on Cancer estimated about 20 million new cancer cases and 9.7 million cancer deaths in 2022, with new cases projected to reach roughly 35 million by 2050. For health systems and cancer centers, this creates a clear mandate: expand access to minimally invasive cancer treatment, build integrated interventional radiology capacity, and align clinical pathways with evidence-based oncology guidelines.

Transformative Shifts in the Interventional Oncology Landscape

The interventional oncology landscape is shifting from procedure-based service lines toward integrated, disease-specific cancer programs. Hospitals are increasingly embedding interventional radiologists in tumor boards, liver cancer clinics, lung nodule programs, and metastatic disease pathways so that patients are evaluated earlier for ablation, embolization, and locoregional therapy rather than only after multiple treatment failures.

Technology is also reshaping clinical delivery. Cone-beam CT, fusion imaging, navigation software, robotic assistance, and advanced embolic platforms are improving procedural planning and targeting. At the same time, oncology is moving toward combination strategies, including locoregional therapy paired with immunotherapy or targeted agents, particularly in hepatocellular carcinoma, where major clinical guidelines recognize TACE, ablation, and radioembolization as important options for selected patients.

Cumulative Impact of Artificial Intelligence in Interventional Oncology

Artificial intelligence is becoming a cumulative force across the interventional oncology workflow. In screening and diagnosis, AI-enabled imaging tools can help detect lesions, characterize tumor boundaries, and prioritize cases for specialist review. During planning, segmentation and radiomics can support volumetric assessment, ablation margin estimation, and patient selection for image-guided cancer therapy.

The operational value is equally important. AI can support scheduling, inventory planning, radiation dose management, and outcomes tracking across interventional oncology programs. As adoption matures, the highest-impact use cases will likely combine validated algorithms with structured clinical data, multidisciplinary review, and real-world evidence registries that measure local control, survival, complications, length of stay, and patient-reported outcomes.

Key Regional Insights: Global Interventional Oncology Demand

Asia-Pacific is positioned for rapid interventional oncology expansion because it carries a high burden of liver, lung, gastric, and colorectal cancers, while major markets such as China, Japan, South Korea, India, and Australia continue investing in advanced imaging and cancer infrastructure. North America remains a global innovation hub, supported by large academic cancer centers, established reimbursement pathways for many image-guided procedures, and strong adoption of tumor ablation, TACE, and Y-90 radioembolization.

Europe benefits from mature oncology networks and guideline-driven care, with Germany, France, Italy, Spain, and the United Kingdom driving procedure standardization and clinical research. Latin America, led by Brazil and Mexico, is expanding access to minimally invasive cancer treatment but still faces uneven distribution of specialist centers. The Middle East is investing in tertiary hospitals and oncology modernization, particularly in GCC countries, while Africa remains an access-constrained region where workforce training, imaging availability, cancer screening, and referral pathway development are central to long-term improvement.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining relevance as cancer incidence rises and governments expand tertiary hospital capacity, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines at different stages of interventional oncology adoption. The GCC is accelerating demand through national cancer strategies, advanced hospital construction, oncology center development, and medical tourism, especially in Saudi Arabia, the United Arab Emirates, and Qatar.

The European Union supports interventional oncology through cross-border research collaboration, regulatory harmonization, cancer-plan funding priorities, and guideline-based care, although reimbursement remains country-specific. BRICS countries are important high-need markets because Brazil, Russia, India, China, and South Africa combine large populations with growing oncology infrastructure requirements. G7 countries remain central to clinical evidence generation, advanced imaging adoption, and premium technology uptake, while NATO members overlap with many high-income health systems that prioritize resilient medical infrastructure, imaging capacity, and advanced cancer care readiness.

Key Country Insights: Priority Markets for Interventional Oncology

The United States leads in academic interventional oncology, clinical trials, Y-90 radioembolization adoption, tumor ablation, and multidisciplinary cancer care, while Canada shows strong adoption in urban cancer centers but faces geographic access challenges across remote and rural areas. Mexico and Brazil are expanding minimally invasive oncology services through major public and private hospitals, although affordability, reimbursement variability, and regional disparities remain barriers. In Europe, the United Kingdom, Germany, France, Italy, and Spain have established interventional radiology networks and guideline-driven oncology systems, while Russia has significant oncology demand and uneven access across regions.

China is scaling interventional oncology rapidly through hospital expansion, high liver cancer demand, and growing advanced imaging capacity; India is growing through private oncology networks, public cancer initiatives, medical tourism, and rising interventional radiology capability. Japan and South Korea are advanced markets with strong expertise in hepatocellular carcinoma management, ablation, and image-guided interventions. Australia combines high-quality cancer care with centralized specialist services, making referral optimization, telehealth-enabled care coordination, and rural access important priorities.

Actionable Recommendations for Interventional Oncology Leaders

Industry leaders should build interventional oncology programs around disease-specific pathways, not isolated procedures. The strongest near-term opportunities are in hepatocellular carcinoma, colorectal liver metastases, lung tumors, renal tumors, and bone metastasis palliation, where image-guided therapy can reduce recovery time and support multidisciplinary treatment sequencing.

Hospitals should invest in interventional radiology workforce development, advanced imaging, ablation platforms, embolization capabilities, radiation safety, and outcomes registries. Device and technology providers should prioritize evidence generation, physician training, patient selection tools, and workflow integration. Payers and policymakers should assess value using procedure safety, length of stay, repeat treatment rates, quality of life, and total cost of care rather than device cost alone.

Research Methodology

This executive summary is based on a structured review of public health data, cancer epidemiology, clinical practice guidelines, peer-reviewed literature, regulatory information, and observable adoption patterns in interventional oncology. Core references include internationally recognized sources such as the International Agency for Research on Cancer, World Health Organization materials, national cancer agencies, and professional society guidance in oncology and interventional radiology.

The analysis emphasizes verified, data-backed indicators rather than speculative claims. Market interpretation was developed by triangulating cancer burden, procedure relevance, healthcare infrastructure, technology adoption, reimbursement maturity, regional access conditions, and the role of multidisciplinary cancer care across leading and emerging markets.

Conclusion: Interventional Oncology as a Strategic Growth Platform

Interventional oncology is moving from a specialized procedural niche to a strategic cancer-care capability. The convergence of rising cancer incidence, advanced imaging, minimally invasive therapy, AI-enabled planning, and multidisciplinary decision-making is expanding its role across diagnosis, local tumor control, palliation, and combination treatment pathways.

Organizations that invest now in clinical integration, evidence-based protocols, patient access, and measurable outcomes will be best positioned to lead. In a cancer landscape defined by complexity and capacity pressure, interventional oncology offers a scalable, precision-focused approach to improving care delivery and patient experience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Interventional Oncology Market, by Product Type

  • 7.1. Ablation Devices
  • 7.2. Embolization Devices
  • 7.3. Support & Access Devices

8. Interventional Oncology Market, by Procedure Type

  • 8.1. Tumor Ablation Procedures
  • 8.2. Vascular Interventions
  • 8.3. Tumor Biopsy Procedures
  • 8.4. Palliative Procedures

9. Interventional Oncology Market, by Cancer Type

  • 9.1. Liver Cancer
  • 9.2. Lung Cancer
  • 9.3. Kidney (Renal) Cancer
  • 9.4. Breast Cancer

10. Interventional Oncology Market, by End-Use

  • 10.1. Hospitals
  • 10.2. Specialty Clinics

11. Interventional Oncology Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Interventional Oncology Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Interventional Oncology Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Accuray Incorporated
  • 15.2. Baxter International Inc.
  • 15.3. Bayer AG
  • 15.4. Becton, Dickinson and Company
  • 15.5. Boston Scientific Corporation
  • 15.6. Cook Medical Inc.
  • 15.7. GE HealthCare Technologies Inc.
  • 15.8. Johnson & Johnson Services, Inc.
  • 15.9. Koninklijke Philips N.V.
  • 15.10. Medtronic plc
  • 15.11. Merit Medical Systems, Inc.
  • 15.12. Profound Medical Corp.
  • 15.13. Siemens Healthineers AG
  • 15.14. Sirtex Medical Limited
  • 15.15. Teleflex Incorporated
  • 15.16. Terumo Corporation
  • 15.17. Varian Medical Systems, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTERVENTIONAL ONCOLOGY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL INTERVENTIONAL ONCOLOGY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL INTERVENTIONAL ONCOLOGY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL INTERVENTIONAL ONCOLOGY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL INTERVENTIONAL ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ABLATION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ABLATION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ABLATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EMBOLIZATION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EMBOLIZATION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EMBOLIZATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SUPPORT & ACCESS DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SUPPORT & ACCESS DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SUPPORT & ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUMOR ABLATION PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TUMOR ABLATION PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUMOR ABLATION PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VASCULAR INTERVENTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VASCULAR INTERVENTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VASCULAR INTERVENTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TUMOR BIOPSY PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TUMOR BIOPSY PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TUMOR BIOPSY PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PALLIATIVE PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PALLIATIVE PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PALLIATIVE PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIVER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIVER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL KIDNEY (RENAL) CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL KIDNEY (RENAL) CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL KIDNEY (RENAL) CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 67. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 72. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 82. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 83. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPEAN UNION INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPEAN UNION INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 92. BRICS INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. BRICS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 97. G7 INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. G7 INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. G7 INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. G7 INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. G7 INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 102. NATO INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. NATO INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. NATO INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NATO INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NATO INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. UNITED STATES INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. UNITED STATES INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 113. CANADA INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. CANADA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. CANADA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. CANADA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. CANADA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 118. MEXICO INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. MEXICO INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. MEXICO INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MEXICO INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MEXICO INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 123. BRAZIL INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. BRAZIL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRAZIL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. BRAZIL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. BRAZIL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED KINGDOM INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED KINGDOM INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED KINGDOM INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED KINGDOM INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED KINGDOM INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 133. GERMANY INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. GERMANY INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GERMANY INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. GERMANY INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. GERMANY INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 138. FRANCE INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. FRANCE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. FRANCE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. FRANCE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. FRANCE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 143. RUSSIA INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. RUSSIA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. RUSSIA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. RUSSIA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. RUSSIA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 148. ITALY INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. ITALY INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ITALY INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ITALY INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ITALY INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 153. SPAIN INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. SPAIN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. SPAIN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. SPAIN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. SPAIN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 163. INDIA INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. INDIA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. INDIA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. INDIA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. INDIA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 168. JAPAN INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. JAPAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. JAPAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. JAPAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. JAPAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 173. AUSTRALIA INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. AUSTRALIA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. AUSTRALIA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AUSTRALIA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AUSTRALIA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 178. SOUTH KOREA INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. SOUTH KOREA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. SOUTH KOREA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. SOUTH KOREA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. SOUTH KOREA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)